CN111184725B - Medicinal preparation for preventing and treating cerebral infarction and preparation method thereof - Google Patents
Medicinal preparation for preventing and treating cerebral infarction and preparation method thereof Download PDFInfo
- Publication number
- CN111184725B CN111184725B CN202010124089.8A CN202010124089A CN111184725B CN 111184725 B CN111184725 B CN 111184725B CN 202010124089 A CN202010124089 A CN 202010124089A CN 111184725 B CN111184725 B CN 111184725B
- Authority
- CN
- China
- Prior art keywords
- water
- compound
- injection
- preparation
- cerebral infarction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010008118 cerebral infarction Diseases 0.000 title claims abstract description 43
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 20
- 229940126062 Compound A Drugs 0.000 claims abstract description 19
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000003937 drug carrier Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 39
- 239000008215 water for injection Substances 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 17
- 239000000839 emulsion Substances 0.000 claims description 16
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 13
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 13
- 235000010445 lecithin Nutrition 0.000 claims description 13
- 239000000787 lecithin Substances 0.000 claims description 13
- 229940067606 lecithin Drugs 0.000 claims description 13
- 229920001993 poloxamer 188 Polymers 0.000 claims description 13
- 229940044519 poloxamer 188 Drugs 0.000 claims description 13
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 13
- 229920000053 polysorbate 80 Polymers 0.000 claims description 13
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 10
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 229940093471 ethyl oleate Drugs 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000001804 emulsifying effect Effects 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 238000010253 intravenous injection Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 2
- 239000011261 inert gas Substances 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 21
- 229940079593 drug Drugs 0.000 abstract description 15
- 241000700159 Rattus Species 0.000 description 17
- 201000006474 Brain Ischemia Diseases 0.000 description 8
- 206010008120 Cerebral ischaemia Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 206010061216 Infarction Diseases 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 210000004004 carotid artery internal Anatomy 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000007946 glucose deprivation Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000007971 neurological deficit Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 229960000715 nimodipine Drugs 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- NDYYBQHNPPJCSU-UHFFFAOYSA-N 2,3,4,4a-tetrahydropyrrolo[2,3-e]thiazine Chemical class S1NCCC2N=CC=C21 NDYYBQHNPPJCSU-UHFFFAOYSA-N 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010060965 Arterial stenosis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000002551 anterior cerebral artery Anatomy 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pharmaceutical preparation for preventing and treating cerebral infarction and a preparation method thereof, wherein the pharmaceutical preparation is prepared from a compound A shown in the following structural formula, optional other drugs for preventing and treating cerebral infarction and a pharmaceutically acceptable carrier. The invention also provides application of the compound A in preparing a medicine for preventing and treating cerebral infarction.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a pharmaceutical preparation for preventing and treating cerebral infarction and a preparation method thereof.
Background
Cerebral infarction (also known as cerebral infarction) and ischemic stroke (cerebral ischemic stroke) is an acute cerebrovascular disease with extremely high fatality rate and disability rate and seriously threatening human life and health, and usually refers to ischemic necrosis or softening of local brain tissue caused by ischemia and hypoxia caused by cerebral blood flow supply disorder. Cerebral infarction is a sudden brain disease, has rapid onset of disease, mostly has no obvious prodromal symptoms, and is mainly characterized by speech disturbance, hemiplegia, sudden syncope and unconsciousness in clinical manifestation.
Cerebral infarction may be caused by the gradual formation of thrombus in the lumen of an artery, which eventually blocks the artery due to arterial stenosis. Another common cause of cerebral infarction is the detachment of tiny emboli on the inner wall of cerebral vessels or mural thrombus of heart valves, which flow to cerebral arteries and cause embolism. No matter what kind of reason causes the cerebral infarction, all can take place in any age bracket, and have the trend of gradually rising along with the age, is mostly seen in the middle-aged and old people of 45 ~ 70 years old. Cerebral infarction not only poses a great threat to human health and life, but also brings great pain and heavy burden to patients, families and society.
Cerebral infarction belongs to difficult diseases, effective treatment measures are always lacked in medicine at present, only few kinds of thrombolytic drugs, surgical operations and the like are available in clinical treatment of cerebral infarction, and the clinical use time window is very short. In view of the serious hazard of cerebral infarction, there is an unmet need in the art for a drug for preventing cerebral infarction.
Disclosure of Invention
The invention aims to solve the technical problem of finding an effective medicament for preventing and treating cerebral infarction and a preparation method thereof.
The inventors of the present invention have completed the present invention based on the following unexpected findings: n- [ (4aR,7aS) -6- [ 5-fluoro-4- (1-hydroxy-1-methyl-ethyl) -6-methyl-pyrimidin-2-yl ] -7 a-phenyl-4, 4a,5, 7-tetrahydropyrrolo [3,4-d ] [1,3] thiazin-2-yl ] benzamide hydrochloride (hereinafter referred to aS Compound A) having the following structural formula
Has the application of preventing and/or treating cerebral infarction. Based on this, the inventors studied and developed a pharmaceutical preparation suitable for the prevention and treatment of cerebral infarction and a method for producing the same.
To this end, in one aspect, the present invention provides a pharmaceutical preparation for the prevention and treatment of cerebral infarction, wherein the pharmaceutical preparation is prepared from compound a, optionally other drugs for the prevention and treatment of cerebral infarction, and a pharmaceutically acceptable carrier.
In one aspect, the pharmaceutical preparation contains other drugs for preventing and treating cerebral infarction, wherein the drugs are selected from one or more of urokinase, heparin sodium, nimodipine, aspirin and tanshinone IIA.
In one aspect, the pharmaceutical formulation is free of other drugs for preventing and treating cerebral infarction.
In one aspect, the pharmaceutical formulation is in the form of an emulsion suitable for intravenous injection, and the pharmaceutically acceptable carrier consists of ethyl oleate, lecithin, poloxamer 188, tween 80, propylene glycol, and water for injection.
In one aspect, per 100ml of the emulsion comprises:
the rest is water for injection.
In one aspect, per 100ml of the emulsion comprises:
the rest is water for injection.
In one aspect, the method of preparing the pharmaceutical formulation comprises the steps of:
(1) fully mixing the compound A, lecithin, poloxamer 188, tween 80, propylene glycol and water for injection accounting for 50% -70% of the total volume until the mixture is completely dissolved under the condition of heating and stirring to form a water phase;
(2) slowly dripping ethyl oleate into the water phase under the condition that the water phase is kept under heating and stirring, keeping for 10-20 minutes under the condition that the water phase is heated and stirred after mixing is finished, and then adding the rest of water for injection to a constant volume to obtain primary emulsion;
(3) emulsifying the primary emulsion for 2-4 times by high pressure homogenizing machine, filtering with 0.8 micrometer and 0.22 micrometer microporous filter membranes, packaging in appropriate container, charging inert gas, and sealing.
In one aspect, the conditions of the heating and stirring in the steps (1) and (2) refer to conditions of a temperature of 50-70 ℃ and a stirring speed of 4000-.
The compounds A used in the present invention are previously described in patent document WO2013/151832A 1. This patent document relates generally to novel tetrahydropyrrolothiazine compounds that are potent inhibitors of beta-site amyloid precursor protein cleaving enzyme (BACE), which are believed to be useful for inhibiting BACE and inhibiting the production of a β peptide, and thus for treating alzheimer's disease or for preventing progression from mild cognitive impairment to alzheimer's disease. In this patent document, the chemical formula, structural formula and synthesis method of compound a are disclosed in example 22. However, this patent document does not mention that the compound has any pharmacological activity in preventing and treating cerebral infarction, which constitutes an unexpected finding of the present invention.
The invention also provides application of the compound A in preparing a medicament for preventing and treating cerebral infarction.
In one aspect, the medicament is a pharmaceutical formulation as described above.
Detailed Description
Preferred embodiments of the present invention and effects thereof will be described in further detail with reference to specific examples. It should be understood, however, that these preferred embodiments are provided to further illustrate the features and advantages of the present invention and are not to be construed as limiting the claims in any way.
Example 1
The components and the dosage of the pharmaceutical preparation for preventing and treating cerebral infarction in the embodiment are shown in the following table:
| components | Dosage of |
| Compound A | 2.5g |
| Oleic acid ethyl ester | 20g |
| Lecithin | 1.2g |
| Poloxamer 188 | 1.2g |
| Tween 80 | 5g |
| Propylene glycol | 2g |
| Water for injection | Adding to 100ml |
The preparation method of the pharmaceutical preparation comprises the following steps:
(1) fully mixing the compound A, lecithin, poloxamer 188, tween 80, propylene glycol and 60mL of water for injection at the temperature of 60 ℃ and the stirring speed of 6000 rpm until the compound A, the lecithin, the poloxamer 188, the tween 80 and the propylene glycol are completely dissolved to form a water phase;
(2) slowly dripping ethyl oleate into the water phase under the conditions that the temperature of the water phase is kept at 60 ℃ and the stirring speed is 6000 rpm, keeping the water phase at the temperature of 60 ℃ and the stirring speed is 6000 rpm for 15 minutes after mixing, and adding the rest of water for injection to a constant volume to obtain primary emulsion;
(3) emulsifying the primary emulsion for 3 times by high pressure homogenizing machine, filtering with 0.8 micrometer and 0.22 micrometer microporous filter membrane, subpackaging in 10mL ampoule, charging nitrogen gas, and sealing.
Example 2
The components and the dosage of the pharmaceutical preparation for preventing and treating cerebral infarction in the embodiment are shown in the following table:
| components | Dosage of |
| Compound A | 5g |
| Oleic acid ethyl ester | 20g |
| Lecithin | 1.2g |
| Poloxamer 188 | 1.2g |
| Tween 80 | 5g |
| Propylene glycol | 2g |
| Water for injection | Adding to 100ml |
The preparation method of the pharmaceutical preparation comprises the following steps:
(1) fully mixing the compound A, lecithin, poloxamer 188, tween 80, propylene glycol and 60mL of water for injection at the temperature of 60 ℃ and the stirring speed of 6000 rpm until the compound A, the lecithin, the poloxamer 188, the tween 80 and the propylene glycol are completely dissolved to form a water phase;
(2) slowly dripping ethyl oleate into the water phase under the conditions that the temperature of the water phase is kept at 60 ℃ and the stirring speed is 6000 rpm, keeping the water phase at the temperature of 60 ℃ and the stirring speed is 6000 rpm for 15 minutes after mixing, and adding the rest of water for injection to a constant volume to obtain primary emulsion;
(3) emulsifying the primary emulsion for 3 times by high pressure homogenizing machine, filtering with 0.8 micrometer and 0.22 micrometer microporous filter membrane, subpackaging in 10mL ampoule, charging nitrogen gas, and sealing.
Example 3
The components and the dosage of the pharmaceutical preparation for preventing and treating cerebral infarction in the embodiment are shown in the following table:
| components | Dosage of |
| Compound A | 10g |
| Oleic acid ethyl ester | 20g |
| Lecithin | 1.2g |
| Poloxamer 188 | 1.2g |
| Tween 80 | 5g |
| Propylene glycol | 2g |
| Water for injection | Adding to 100ml |
The preparation method of the pharmaceutical preparation comprises the following steps:
(1) fully mixing the compound A, lecithin, poloxamer 188, tween 80, propylene glycol and 60mL of water for injection at the temperature of 60 ℃ and the stirring speed of 6000 rpm until the compound A, the lecithin, the poloxamer 188, the tween 80 and the propylene glycol are completely dissolved to form a water phase;
(2) slowly dripping ethyl oleate into the water phase under the conditions that the temperature of the water phase is kept at 60 ℃ and the stirring speed is 6000 rpm, keeping the water phase at the temperature of 60 ℃ and the stirring speed is 6000 rpm for 15 minutes after mixing, and adding the rest of water for injection to a constant volume to obtain primary emulsion;
(3) emulsifying the primary emulsion for 3 times by high pressure homogenizing machine, filtering with 0.8 micrometer and 0.22 micrometer microporous filter membrane, subpackaging in 10mL ampoule, charging nitrogen gas, and sealing.
Example 4
The purpose of this experiment was to investigate the neuronal protective effect of compound a of the present invention using an ex vivo cerebral ischemia model of glucose and glucose deprivation (OGD).
The experimental method of this experiment is as follows:
with reference to the methods disclosed in "establishment of model of persistent glucose deprivation in PC12 cells", military medicine ", vol.35, 3 rd, p.189-192, 3.2011, PC12 cells were used to establish model of persistent glucose deprivation isolated cerebral ischemia. Specifically, PC12 in logarithmic growth phaseCells were as per 6X 105The cells/ml were seeded at a density of 100. mu.l/well in sterile 96-well plates, incubated in a humidified incubator for 24h, the plates were removed and washed 2 times (5 min/time) with 37 ℃ pre-warmed PBS to remove glucose. Then, a solution containing 5X 10 of the active ingredient was added to each well of a 96-well plate4U/ml penicillin and streptomycin in sugar-free serum-free medium (100. mu.l/well with or without test drugs as shown in Table 1 below); as a control group, a control group containing glucose (1.0g/L), 10% fetal bovine serum and 5X 10 cells was added to each well of a 96-well plate4U/ml penicillin and streptomycin medium (100. mu.l/well). Finally, the 96-well plate was incubated in a 37 ℃ incubator (the 96-well plate of the oxygen-sugar deprived group was placed in a hypoxia chamber filled with a mixed gas of 95% nitrogen and 5% carbon dioxide) for 30 minutes. After the incubation was completed, the medium was removed, 10. mu.L of MTT (5 mg/mL PBS solution) was added to each well of the 96-well plate and returned to the incubator for further incubation for 3 hours, then the medium was discarded, 100. mu.L of DMSO was added, the mixture was shaken in a water bath at 37 ℃ for 30 minutes, and after the purple crystals were completely dissolved, the absorbance value (OD) at a wavelength of 570 nm was measured with a microplate reader570) And OD of sugar oxygen deprived group570The value is OD of the control group570The percentage of values reflects the survival of PC12 cells.
Statistics of survival for this experiment are presented in table 1.
TABLE 1 survival of PC12 cells treated with different test drugs
| Kind of drug | Drug concentration | Survival rate (%) |
| - | - | 26.3±4.3 |
| Nimodipine | 5mg/ml | 49.9±6.1 |
| Tanshinone IIA | 5mg/ml | 57.2±5.9 |
| Aspirin | 5mg/ml | 43.2±7.2 |
| Compound A | 5mg/ml | 68.2±9.7 |
Note: each test drug is provided with 12 compound holes; results are expressed as mean ± standard deviation.
Generally speaking, the higher the survival rate of PC12 cells after treatment with a drug in a model of sugar-oxygen deprivation isolated cerebral ischemia reflects that the drug has a better protective effect on nerve cell damage caused by cerebral infarction. From the above results, compound a has a significant neuroprotective effect on sugar oxygen deprived PC12 cells, and this neuroprotective effect is superior to the other test drugs of the reference at the same concentration.
Example 5
The purpose of the experiment is to use a rat cerebral ischemia-reperfusion injury model to investigate the pharmacological activity of the pharmaceutical preparation of the invention on cerebral infarction.
1. Laboratory animal
Male adult SD rats weighing 240 g. + -.10 g were used in this experiment. Animals were acclimated for two days at room temperature 23-25 ℃, 50% relative humidity and switching light and dark every 12 hours. The rats were provided with freely accessible clean food and drinking water.
2. Establishment of rat cerebral ischemia reperfusion injury model
Rats were anesthetized with intraperitoneal injection of 25% urethane solution. The rat was then mounted on the operating table in the lateral decubitus position, a median cervical incision was made, the common carotid artery was exposed, and the internal carotid artery was isolated. Then, the common carotid artery and the internal carotid artery are clamped, and the nylon wire is slowly pushed towards the intracranial direction of the internal carotid artery through the main incision of the external carotid artery to reach the thinner anterior cerebral artery, so that the middle cerebral artery is blocked to completely block the local blood flow. After 90 minutes, the nylon thread is pulled out, the artery stump is tied tightly, the wound is sutured, and the establishment of the cerebral ischemia reperfusion injury model of the rat is completed.
3. Dosing regimens
The molded rats were randomly divided into 20 groups, namely, a model control group, an example 1 group, an example 2 group and an example 3 group. Another 20 rats that did not occlude the middle cerebral artery after anesthesia were used as a sham group.
The dosing schedule for each experimental group was as follows:
example 1, example 2, example 3 groups: immediately after the molding was completed, the pharmaceutical preparations of example 1, example 2 and example 3 were each administered by tail intravenous injection at a dose of 1.0mL/kg body weight, followed by administration 1 time per day in the same manner for 3 consecutive days.
Model control group: after completion of molding, physiological saline was immediately administered by tail intravenous injection, followed by administration 1 time per day in the same manner for 3 days continuously.
The sham operation group: the same model as the control group.
4. Observation index
(1) Bederson neurological deficit score:
on the day of experiment completion, evaluation of the model and degradation of a neurological evolution, Stroke, 1986 was used by Bederson JB et al, Rat middle carbohydrate array occlusion; 17(3) 472 + 476, scoring the behavioral deficits of the rats by neurofunctional deficits:
(2) measurement of cerebral ischemic infarct volume and water content:
finally, the rats in each group except the sham group were sacrificed by decapitation. Randomly selecting 5 rats, taking the whole brain, weighing the wet weight of the brain, and slicing. The section is placed in a 2% triphenyltetrazolium chloride (TFC) solution for dyeing for 30min, fixed, and separated into a pale area (an infarct area) and a non-pale area (a normal area), and the weight percentage of the infarct area range to the weight of the brain is taken as the cerebral infarction range.
Another 5 rats were randomly selected, whole brains were taken, brain tissues were dried in an oven at 110 ℃ to constant weight, the dry weight was weighed, and brain water content was calculated. Brain water content (brain tissue wet weight-brain tissue dry weight)/brain tissue wet weight × 100%.
5. Results
The experimental statistics are shown in the following tables 1-2.
TABLE 1 Bederson neurological deficit scores for groups of rats
| Group of | Scoring |
| Artificial operation group | 0 |
| Model control group | 3.78±0.53 |
| EXAMPLE 1 group | 2.96±0.68 |
| EXAMPLE 2 group | 2.27±0.61* |
| EXAMPLE 3 group | 1.39±0.46* |
Note: results are expressed as mean ± standard deviation, p <0.05 compared to model control.
TABLE 2 cerebral ischemic infarct volume and water content of each group of rats
Note: results are expressed as mean ± standard deviation, p <0.05 compared to model control group.
The above results suggest that the pharmaceutical preparation of the present invention can significantly improve the neurological deficit of rats with cerebral ischemia-reperfusion injury models, and reduce the volume and water content of cerebral ischemia infarctions, and the improvement is most significant with the effect of example 3, which indicates that the pharmaceutical preparation of the present invention has a positive correlation between the pharmacological activity of cerebral infarction and the content of compound a in the pharmaceutical preparation. In conclusion, the above results indicate that the pharmaceutical preparation of the present invention can be used for preventing and treating cerebral infarction.
Claims (1)
1. The application of the compound A in preparing a medicinal preparation for preventing and treating cerebral infarction, wherein the medicinal preparation is prepared from the compound A and a pharmaceutically acceptable carrier, wherein the compound A is N- [ (4aR,7aS) -6- [ 5-fluoro-4- (1-hydroxy-1-methyl-ethyl) -6-methyl-pyrimidin-2-yl ] -7 a-phenyl-4, 4a,5, 7-tetrahydropyrrolo [3,4-d ] [1,3] thiazin-2-yl ] benzamide hydrochloride shown in the structural formula
And wherein the pharmaceutical formulation is in the form of an emulsion suitable for intravenous injection and the pharmaceutically acceptable carrier consists of ethyl oleate, lecithin, poloxamer 188, tween 80, propylene glycol and water for injection, and wherein the pharmaceutical formulation comprises, per 100ml of the emulsion:
the balance of water for injection, and wherein the preparation method of the pharmaceutical preparation comprises the following steps:
(1) fully mixing the compound A, lecithin, poloxamer 188, tween 80, propylene glycol and water for injection accounting for 50% -70% of the total volume until the mixture is completely dissolved under the condition of heating and stirring to form a water phase;
(2) slowly dripping ethyl oleate into the water phase under the condition that the water phase is kept under heating and stirring, keeping for 10-20 minutes under the condition that the water phase is heated and stirred after mixing is finished, and then adding the rest of water for injection to a constant volume to obtain primary emulsion;
(3) emulsifying the primary emulsion for 2-4 times by a high-pressure emulsion homogenizer, filtering by 0.8 micron and 0.22 micron microporous filter membranes in sequence, subpackaging in a proper container, filling inert gas, and sealing to obtain the final product, wherein the conditions of heating and stirring in the steps (1) and (2) refer to the conditions of the temperature of 50-70 ℃, the stirring speed of 4000-.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010124089.8A CN111184725B (en) | 2020-02-27 | 2020-02-27 | Medicinal preparation for preventing and treating cerebral infarction and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010124089.8A CN111184725B (en) | 2020-02-27 | 2020-02-27 | Medicinal preparation for preventing and treating cerebral infarction and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111184725A CN111184725A (en) | 2020-05-22 |
| CN111184725B true CN111184725B (en) | 2020-12-01 |
Family
ID=70702709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010124089.8A Active CN111184725B (en) | 2020-02-27 | 2020-02-27 | Medicinal preparation for preventing and treating cerebral infarction and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111184725B (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474151B (en) * | 2009-01-21 | 2011-04-27 | 石河子大学医学院第一附属医院 | Alkannin microemulsion composition |
| CN101601737A (en) * | 2009-02-10 | 2009-12-16 | 魏伟 | A kind of Radix Paeoniae Alba total glucosides and effective ingredient microemulsion thereof |
| CN102000026A (en) * | 2010-10-25 | 2011-04-06 | 徐州医学院 | Naproxen orally-taken micro-emulsion preparation and preparation method thereof |
| JO3143B1 (en) * | 2012-04-03 | 2017-09-20 | Lilly Co Eli | Tetrahydropyrrolothiazine compounds |
| TWI798751B (en) * | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| CN106474061B (en) * | 2016-12-08 | 2019-01-22 | 黑龙江童医生儿童生物制药有限公司 | A kind of Propranolol Hydrochloride Orally taken emulsion and preparation method thereof |
-
2020
- 2020-02-27 CN CN202010124089.8A patent/CN111184725B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111184725A (en) | 2020-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1123359C (en) | Treatment of cerebral ischemia and cerebral damage with neuroprotective agent | |
| CA3205201A1 (en) | Composition comprising (7s)-(+)-cyclopentyl carbarmic acid, 8,8-dimethyl-2-oxo-6,7-dihydro-2h,8h-pyrano[3,2-g]chromen-7-yl-ester as active ingredient for prevention, alleviation, or treatment of eye diseas | |
| WO2009155777A1 (en) | The use and method of the compound of fasudil and the pharmaceutical composition thereof | |
| CN111184725B (en) | Medicinal preparation for preventing and treating cerebral infarction and preparation method thereof | |
| CN114732826A (en) | Application of gamma-aminobutyric acid and spinosyn in prevention, alleviation or treatment of anxiety | |
| CN110664809B (en) | A kind of pharmaceutical composition for preventing and treating cerebral infarction | |
| EP4205734B1 (en) | Alpha-asarone for use in the treatment of hemorrhagic stroke | |
| US6075045A (en) | Method of treating paralysis of the extremities caused by cerebral infarction | |
| CN113925851B (en) | Application of Boropinol-B in preparation of medicine for treating insomnia | |
| RU2148972C1 (en) | Method for treating hemophthalmia | |
| TWI736173B (en) | Mycelium of liquid culture of antrodia camphorata extract, compounds of mycelium of liquid culture of antrodia camphorata extract, and use thereof for treating ischemic stroke | |
| CN116585447A (en) | Cerebral apoplexy combined medicine and application thereof | |
| US20080050426A1 (en) | Method For Preparing Extract From Wild Ginseng Showing Anticancer Activity And The Composition Comprising The Same | |
| CN110787163B (en) | Pharmaceutical composition for neuroprotection and promoting nerve regeneration and preparation thereof | |
| CN119792487B (en) | Drug for preventing and treating ischemic stroke | |
| US8530433B2 (en) | Use of icariside II in manufacture of products for preventing or treating male or female sexual dysfunction | |
| CN113143914A (en) | Application of brucea javanica picrol in preparation of medicine for treating cerebral ischemic stroke | |
| CN105935443A (en) | Pharmaceutical composition for treating diabetic cataract | |
| CN107648236B (en) | Pharmaceutical composition for preventing or treating ischemia/reperfusion injury and application thereof | |
| CN119656164B (en) | Amino acid composition and application thereof | |
| CN108503651A (en) | A kind of spiro-compound for treating cerebral apoplexy | |
| HUT66832A (en) | A stimulator of vascular endothelial cells and use thereof | |
| CN106727605B (en) | Application of cyclovirobuxine D in preparing medicine for preventing or treating cerebral arterial thrombosis | |
| CN111773204A (en) | Application of sodium dichloroacetate in preparing medicine for treating vascular dementia | |
| US20240335395A1 (en) | Compositions and methods for preventing and/or treating disease associated with il-23 expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |